Bmx-CreERT2 Mouse

Random Transgenic

Bmx-CreERT2 Random Transgenic Mouse Model
This line is cryopreserved and requires cryorecovery.

C57BL/6J Background

  • Model #
  • Genotype
  • Nomenclature
  • 14081-F
  • 14081-M
  • An inducible cre deleter under the control of the BMX non-receptor tyrosine kinase promoter.
  • Cre recombination is inducible via administration of tamoxifen.
  • Useful for study of angiogenesis, atherosclerosis and neovascularization.
  • Non-induced Bmx-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Bmx-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in endothelial cells (95%+).

Genetic Background:



The Bmx-Cre-ERT2 mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Bmx promoter fragment fused to a CreERT2 cDNA into B6xCBA F1 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2015.


Cancer Research Technology (CRT)



Access to this model requires execution of a Limited Breeding Agreement and cryorecovery services to recover the line. Current Limited Breeding Agreement fees for this model are $3,000/€2550 per year for non-profit users and $10,000/€8500 per year for for-profit users. Cryorecovery fees are additional.

Welcome! Tell us a little about yourself